UNISOUND AI TECHNOLOGY CO., LTD.
雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

VOLUNTARY ANNOUNCEMENT
INTENTION TO REPURCHASE SHARES ON THE MARKET

This announcement is made by Unisound AI Technology Co., Ltd. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company of the update regarding its intention to conduct share repurchase of H shares on the market.

Reference is made to (i) the circular of the Company dated June 5, 2026 (the "**Circular**") and (ii) the poll results of the 2025 annual general meeting (the "**AGM**") of the Company dated June 26, 2026, in relation to, among other things, the granting of a general mandate to the board of directors (the "**Board**") of the Company to repurchase H Shares of the Company (the "**Repurchase Mandate**").

Pursuant to the Repurchase Mandate, the Board is authorized to repurchase up to 4,510,988 H shares of the Company (the "**H Shares**") during the validity period of the Repurchase Mandate, representing 10% of the total number of issued H Shares (excluding treasury shares, if any) as at the date of the AGM. The term of the Repurchase Mandate shall commence from the date of approval by the AGM and shall continue until the earliest of: (1) the conclusion of the 2026 annual general meeting of the Company to be held in 2027; (2) the expiry of 12 months from the date of approval of the Repurchase Mandate by the AGM; or (3) the date on which the Repurchase Mandate is revoked or varied by a resolution passed at any general meeting of the Company.

The 11th meeting of the third Board of the Company has resolved to approve a plan to repurchase H Shares with an aggregate value not exceeding HK$0.1 billion on the open market within a period of 6 months from the date of this announcement (the "**Proposed Share Repurchase**"), subject to the Repurchase Mandate.

Depending on the circumstances at the time of repurchase, the H Shares repurchased by the Company will be used for cancellation with a corresponding reduction in the registered capital, or held as treasury shares. The Company plans to utilize its own funds and self-raised funds, which may be legally applied for such purposes under the Company's articles of association and applicable laws, regulations and rules of the PRC, to finance the Proposed Share Repurchase.

The Board is of the view that the Proposed Share Repurchase under the current circumstances can demonstrate the Company's confidence in its own business prospects and outlook, and will ultimately bring benefits to the Company and create value for the shareholders. In addition, the Board is of the view that the Company's existing financial resources are sufficient to support the Proposed Share Repurchase while maintaining a sound financial position.

The Company will conduct the Proposed Share Repurchase in compliance with the Company's articles of association, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Codes on Takeovers and Mergers and Share Buy-backs, and all applicable laws and regulations with which the Company is required to comply. The Board has no intention to exercise the share repurchase mandate in a manner that would result in the number of shares held by the public falling below the minimum public float requirement as prescribed under the Listing Rules.

Shareholders and potential investors should note that the exercise of the Repurchase Mandate by the Company will be subject to market conditions and the absolute discretion of the Board. There is no assurance as to the timing, quantity or price of any repurchase. Accordingly, shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and Chief Executive Officer

Beijing, the PRC
July 23, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; and (ii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.